Tango Therapeutics

Tango Therapeutics

Biotechnology
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

$3.7B

Market Cap • 11/17/2026

2020

(6 years)

Founded

2021

(5 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

3,8

P/S

—

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

5,8

EPS

—

Market Cap

Market Cap

3,7B

EV

2,8B

EV/Revenue

—

EV/EBITDA

-12,3

EV/EBIT

-12,3

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-26%

Total Yield

-26%

Payout

0%

Retained Earnings

-772,4M

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

15,5%

Capex/OCF

-0,2%

SBC/OCF

—

% PPE

3,7%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Revenue 5Y

-100%

CAGR Op. Income 5Y

38,3%

CAGR Net Income 5Y

35,9%

CAGR EPS 5Y

9,3%

CAGR OCF 5Y

30,1%

Leverage

N.D./EBITDA

4,2

Debt/Equity

0%

Current Ratio

39,4

Quick Ratio

38,8

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium